Literature DB >> 10413033

Neuroprotective effects of a novel nitrone, NXY-059, after transient focal cerebral ischemia in the rat.

S Kuroda1, R Tsuchidate, M L Smith, K R Maples, B K Siesjö.   

Abstract

Recent results have demonstrated that the spin trapping agent alpha-phenyl-N-tert-butyl nitrone (PBN) reduces infarct volume in rats subjected to 2 hours of middle cerebral artery occlusion, even when given 1 to 3 hours after the start of recirculation. In the current study, the authors assessed the effect of NXY-059, a novel nitrone that is more soluble than PBN. Loading doses were given of 0.30, 3.0, or 30 mg x kg(-1) followed by 0.30, 3.0, or 30 mg x kg(-1) x h(-1) for 24 or 48 hours. Dose-response studies showed that when treatment was begun 1 hour after recirculation, 0.30 mg x kg(-1) had a small and 30 mg x kg(-1) a marked effect on infarct volume. At equimolar doses (3.0 mg x kg(-1) for NXY-059 and 1.4 mg x kg(-1) for PBN), NXY-059 was more efficacious than PBN. Similar results were obtained when a recovery period of 7 days was allowed. The window of therapeutic opportunity for NXY-059 was 3 to 6 hours after the start of recirculation. Studies of the transfer constant of [14C]NXY-059 showed that, in contrast to PBN, this more soluble nitrone penetrates the blood-brain barrier less extensively. This fact, and the pronounced antiischemic effect of NXY-059, suggest that the delayed events leading to infarction may be influenced by reactions occurring at the blood-endothelial interface.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10413033     DOI: 10.1097/00004647-199907000-00008

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  51 in total

Review 1.  A radical approach to stroke therapy.

Authors:  J McCulloch; D Dewar
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-25       Impact factor: 11.205

2.  De-Risking of Stilbazulenyl Nitrone (STAZN), a Lipophilic Nitrone to Treat Stroke Using a Unique Panel of In Vitro Assays.

Authors:  Paul A Lapchak; David R Schubert; Pamela A Maher
Journal:  Transl Stroke Res       Date:  2011-06       Impact factor: 6.829

Review 3.  Neuroprotection for ischemic stroke: past, present and future.

Authors:  Myron D Ginsberg
Journal:  Neuropharmacology       Date:  2008-03-04       Impact factor: 5.250

Review 4.  Neuroprotection in cerebral ischemia: emphasis on the SAINT trial.

Authors:  Marcus R Chacon; Matt B Jensen; Justin A Sattin; Justin A Zivin
Journal:  Curr Cardiol Rep       Date:  2008-02       Impact factor: 2.931

Review 5.  Clinical trials in acute ischemic stroke.

Authors:  Kiyoshi Kikuchi; Eiichiro Tanaka; Yoshinaka Murai; Salunya Tancharoen
Journal:  CNS Drugs       Date:  2014-10       Impact factor: 5.749

6.  Non-invasive treatment with near-infrared light: A novel mechanisms-based strategy that evokes sustained reduction in brain injury after stroke.

Authors:  Christos D Strubakos; Michelle Malik; Joseph M Wider; Icksoo Lee; Christian A Reynolds; Panayiotis Mitsias; Karin Przyklenk; Maik Hüttemann; Thomas H Sanderson
Journal:  J Cereb Blood Flow Metab       Date:  2019-05-21       Impact factor: 6.200

7.  Why Have Clinical Trials of Antioxidants to Prevent Neurodegeneration Failed? - A Cellular Investigation of Novel Phenothiazine-Type Antioxidants Reveals Competing Objectives for Pharmaceutical Neuroprotection.

Authors:  Maike J Ohlow; Selina Sohre; Matthias Granold; Mathias Schreckenberger; Bernd Moosmann
Journal:  Pharm Res       Date:  2016-11-28       Impact factor: 4.200

8.  Anti-inflammatory agent, OKN-007, reverses long-term neuroinflammatory responses in a rat encephalopathy model as assessed by multi-parametric MRI: implications for aging-associated neuroinflammation.

Authors:  Rheal A Towner; Debra Saunders; Nataliya Smith; Rafal Gulej; Tyler McKenzie; Brandy Lawrence; Kathryn A Morton
Journal:  Geroscience       Date:  2019-09-02       Impact factor: 7.713

9.  The use of the Chandler loop to examine the interaction potential of NXY-059 on the thrombolytic properties of rtPA on human thrombi in vitro.

Authors:  N J Mutch; N R Moore; C Mattsson; H Jonasson; A R Green; N A Booth
Journal:  Br J Pharmacol       Date:  2007-11-05       Impact factor: 8.739

10.  Translational stroke research using a rabbit embolic stroke model: a correlative analysis hypothesis for novel therapy development.

Authors:  Paul A Lapchak
Journal:  Transl Stroke Res       Date:  2010-04-02       Impact factor: 6.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.